Goldman Sachs reduces share in Orphazyme and drops below 5 percent boundary

Orphazyme's life on the stock exchange has been hectic in recent weeks.


US company Goldman Sachs has divested shares in Danish biotech firm Orphazyme, and as of June 17, owns less than 5 percent of the company, Orphazyme reported on Wednesday.

Goldman Sachs' ownership share in the biotech firm has been going up and down for a while. Orphazyme's announcement indicates that the firm reached 5.38 percent ownership on June 16, only to sell out again the next day.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs